Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Inclusion Criteria:

• Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients
• second line
• ECOG 0～2
• Patients with normal liver function and renal function

Exclusion Criteria:

• Patients with severe acute infection requiring antibiotic therapy
• Patients who have received treatment in other areas of cancer within 5 years
• During pregnancy and lactation patients